Parenteral Drugs Market Predicted to Reach Maximum Revenue and CAGR during 2019 to 2029
Verfasser: ashwani_kailiya on Monday, 3 February 2020As the complexity of active pharmaceutical ingredients goes up, and includes small molecule options and biologics, the number of parenteral drugs has gone up as well. The number of new molecular products which have received the approval of regulatory bodies such as the FDA has gone up and has aided the growth of the industry for the foreseeable future. Major players in the parenteral drugs market are focusing their efforts on expanding their operations in terms of new countries to leverage opportunities in untapped markets, and also setting up new facilities for target markets. In a bid to secure a larger share of the market, manufacturers are also investing in the consolidation of extant production facilities.
Asia Pacific Being Targeted by Manufacturers
Major pharmaceutical companies from around the world are seeking the acquisition of smaller regional competitors, particularly those in the emerging markets of the Asia Pacific region, with the aim of maintaining sustainable rates of growth in terms of parenteral drugs. Further hospital pharmacies are gaining importance as primary channels of distribution owing to higher rates of hospitalization and the rising availability of requisitely skilled man power resources. Similar growth is also being projected for revenue being made by retail pharmacies.